Text Size

Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1

This study has been completed.
Sponsor:
Collaborator:
Friends Research Institute, Inc.
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000245
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: May 1994
History of Changes
  Purpose

The purpose of this study is to confirm whether a blood level ""ceiling"" exists on desipramine effect in cocaine abuse.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Drug: Desipramine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Evaluation of a Desipramine Ceiling in Cocaine Abuse

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Craving
  • Retention
  • Cocaine use
  • Depression
  • Anxiety
  • Mood indicators

Estimated Enrollment: 0
Study Start Date: May 1994
Estimated Study Completion Date: December 2001
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000245

Locations
United States, California
Friends Research Institute
Los Angeles, California, United States, 90025
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Friends Research Institute, Inc.
Investigators
Principal Investigator: Frank Gawin, M.D. Friends Research Institute, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000245     History of Changes
Other Study ID Numbers: NIDA-08082-1, R01-08082-1
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Desipramine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Antidepressive Agents
 Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013